Triptolide induces ferroptosis in lung adenocarcinoma cell by modulating lipid metabolism pathways
- 1Clinical Medical Center of Oncology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine
Abstract
To investigate the mechanism by which Triptolide (TPL) regulates ferroptosis in lung cancer cells through a comprehensive approach integrating network pharmacology, molecular docking, molecular dynamics simulations, and in vitro validation. The CCK-8 assay was initially used to examine the inhibitory effects of varying concentrations of TPL on the proliferation of human lung adenocarcinoma (LAD) cells. The objective is to identify ferroptosis-related pathway targets from the FerrDb database. Then, the intersection of the three should be determined to obtain potential ferroptosis targets regulated by TPL treatment in LUAD. Secondly, a protein-protein interaction network was constructed using the STRING database and Cytoscape software. Subsequently, network submodule analysis was performed based on the MCODE algorithm. Enrichment analysis revealed the key regulatory pathways through which TPL combats lung cancer. Molecular docking and kinetic simulations provided a detailed exploration of the potential mechanism by which TPL inhibits lung cancer via the ferroptosis pathway, with in vitro experiments providing validation. Finally, ADMET analysis was conducted to simulate drug metabolism processes, thereby providing a foundation for its clinical application. The specific experimental workflow is illustrated in Fig. 1. TPL inhibited the proliferation and migration of A549 cells in a concentration‑dependent manner. PPI network and KEGG enrichment analysis identified ferroptosis as the primary pathway targeted by TPL. Molecular docking and MD simulations revealed stable interactions between TPL and GPX4, SLC7A11, and ACSL4. Western blot, flow cytometry, and CETSA validated that TPL directly targets GPX4, SLC7A11, and ACSL4 in A549 cells. ADMET analysis indicated favorable physicochemical properties, oral absorption, and acceptable safety profiles of the ferroptosis pathway regulated by TPL in the context of lung adenocarcinoma. Molecular docking and molecular dynamics simulations revealed stable interactions between TPL and GPX4, SLC7A11, and ACSL4. In vitro studies employing Western Blot, flow cytometry, and Cell Thermal Shift Assay (CETSA) have validated the molecular mechanism by which TPL directly targets GPX4, SLC7A11, and ACSL4. A comprehensive physicochemical and pharmacokinetic analysis was conducted on TPL, revealing its favorable physicochemical properties, drug-like characteristics, and synthetic feasibility. The study further demonstrated significant advantages in oral absorption. Its metabolic pathways are well-defined, posing a low risk of drug interactions. While demonstrating adequate cardiac and hepatic safety, it exhibits a relatively low maximum tolerated dose. TPL inhibits GPX4 and SLC7A11 expression while upregulating ACSL4 in A549 cells, and directly binds to these three proteins. By modulating lipid metabolism, TPL induces ferroptosis, positioning it as a promising therapeutic candidate for LUAD.
Related
- Commentary: Wogonoside alleviates metabolic dysfunction-associated steatohepatitis by modulating AMPK and xCT/GPX4 pathways to restrain lipid dysregulation and ferroptosis
- Chrysanthemum morifolium extract prevents oxidative stress and ferroptosis in cerebral ischemia-reperfusion injury by modulating the miR-144/Nrf2 pathway
- SMCO2 inhibits ferroptosis through the VDAC1–STAT3 axis by modulating MAM homeostasis in ovarian cancer
- Re-Du-Ning Alleviates Airway-Intestinal Inflammation of COPD Rats by Regulating Glycerophospholipid Metabolism and Modulating Gut Microbiome
- Hypothalamic Farnesoid X Receptor deficiency alters energy balance by modulating hepatic glucose production and adipose tissue metabolism through central insulin signaling.
BibTeX
@article{yang2026triptolide,
title = {{Triptolide induces ferroptosis in lung adenocarcinoma cell by modulating lipid metabolism pathways}},
author = {Zhuo Yang and Ziyi Zhou and Lanlan Yang and Xiangyu Ren and Zhenyu Zhao and Yuli Wang and Yan Li and Jianchun Wu},
journal = {Scientific Reports},
year = {2026},
month = sep,
doi = {10.1038/s41598-026-70437-1},
url = {https://doi.org/10.1038/s41598-026-70437-1},
note = {CC BY},
}
RIS
TY - JOUR
TI - Triptolide induces ferroptosis in lung adenocarcinoma cell by modulating lipid metabolism pathways
AU - Zhuo Yang
AU - Ziyi Zhou
AU - Lanlan Yang
AU - Xiangyu Ren
AU - Zhenyu Zhao
AU - Yuli Wang
AU - Yan Li
AU - Jianchun Wu
PY - 2026
DA - 2026/09/01
JO - Scientific Reports
DO - 10.1038/s41598-026-70437-1
UR - https://doi.org/10.1038/s41598-026-70437-1
AB - To investigate the mechanism by which Triptolide (TPL) regulates ferroptosis in lung cancer cells through a comprehensive approach integrating network pharmacology, molecular docking, molecular dynamics simulations, and in vitro validation. The CCK-8 assay was initially used to examine the inhibitory effects of varying concentrations of TPL on the proliferation of human lung adenocarcinoma (LAD) cells. The objective is to identify ferroptosis-related pathway targets from the FerrDb database. Then, the intersection of the three should be determined to obtain potential ferroptosis targets regulated by TPL treatment in LUAD. Secondly, a protein-protein interaction network was constructed using the STRING database and Cytoscape software. Subsequently, network submodule analysis was performed based on the MCODE algorithm. Enrichment analysis revealed the key regulatory pathways through which TPL combats lung cancer. Molecular docking and kinetic simulations provided a detailed exploration of the potential mechanism by which TPL inhibits lung cancer via the ferroptosis pathway, with in vitro experiments providing validation. Finally, ADMET analysis was conducted to simulate drug metabolism processes, thereby providing a foundation for its clinical application. The specific experimental workflow is illustrated in Fig. 1. TPL inhibited the proliferation and migration of A549 cells in a concentration‑dependent manner. PPI network and KEGG enrichment analysis identified ferroptosis as the primary pathway targeted by TPL. Molecular docking and MD simulations revealed stable interactions between TPL and GPX4, SLC7A11, and ACSL4. Western blot, flow cytometry, and CETSA validated that TPL directly targets GPX4, SLC7A11, and ACSL4 in A549 cells. ADMET analysis indicated favorable physicochemical properties, oral absorption, and acceptable safety profiles of the ferroptosis pathway regulated by TPL in the context of lung adenocarcinoma. Molecular docking and molecular dynamics simulations revealed stable interactions between TPL and GPX4, SLC7A11, and ACSL4. In vitro studies employing Western Blot, flow cytometry, and Cell Thermal Shift Assay (CETSA) have validated the molecular mechanism by which TPL directly targets GPX4, SLC7A11, and ACSL4. A comprehensive physicochemical and pharmacokinetic analysis was conducted on TPL, revealing its favorable physicochemical properties, drug-like characteristics, and synthetic feasibility. The study further demonstrated significant advantages in oral absorption. Its metabolic pathways are well-defined, posing a low risk of drug interactions. While demonstrating adequate cardiac and hepatic safety, it exhibits a relatively low maximum tolerated dose. TPL inhibits GPX4 and SLC7A11 expression while upregulating ACSL4 in A549 cells, and directly binds to these three proteins. By modulating lipid metabolism, TPL induces ferroptosis, positioning it as a promising therapeutic candidate for LUAD.
SN - 2045-2322
ER -